COVID19 and its impact on clinical cancer research: the EORTC network experience
30 Jun 2020
By Davi Kaur, Head of Communication, EORTC
Twenty-Twenty will be the year that created worldwide turmoil, not instigated by war but by a virus that migrated from bats to humans, SARS-CoV-2 has ravaged many countries. Like dominoes countries fell, closing their borders trying to tame this disease. The fallout from this pandemic is a global crisis not only financially but also on a social and healthcare perspective.
With the influx of many patients with COVID-19, healthcare systems have been overburdened resulting in all other diseases taking a “backseat” while these patients have been treated. It is estimated that there will be a 5-10% decrease in cancer survival in high-income countries1. For clinical cancer research, many staff and resources had been reassigned to manage COVID 19 patients thereby suspending research activities. Here we asked the EORTC network, on how their institutes have been handling the pandemic and the effect on their research.
In the Netherlands, Professor Martin van den Bent, a neurologist from Erasmus MC – Daniel den Hoed Cancer Center in Rotterdam said, “During the height of the pandemic, clinical research came to a standstill as we tried to avoid patient visits to the hospital. In addition, monitoring and site activation activities were suspended.”
“Initially, all clinical studies were put on-hold during the early days of the COVID-19 outbreak to maximize hospital capacity for COVID-19 cases,” continues Dr Gabe Sonke a medical
oncologist from the Netherlands Cancer Institute in Amsterdam. This was due to the uncertainty of the effect of experimental medication on the risk of infection and severe sequalae and the fact that they could not ensure compliance to trials due to the outbreak. “Studies could get a waiver from a designated hospital committee to restart accrual if expected benefits for patients are
large and impact on hospital resources is limited. As the number of infected patients in our centre remained low and the hospital had taken actions to screen patients entering the building, we were able to re-open all studies,” he said.
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023